‘Increased survival rates’ for bladder cancer patients given immunotherapy drug

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study.

Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years after treatment.

Read full story

Source: Independent, 13 January 2025